Michael Broxson is the founder of Q32 Bio. Q32 Bio has raised $60M in total funding. Latest round: Series B. Based in Cambridge, USA.
Michael Broxson was the CEO of Q32 Bio, a biotechnology company developing biologic therapeutics to restore healthy immune regulation. During his tenure, he oversaw the company's progression to a clinical-stage company with two rapidly advancing clinical programs: ADX-914, an anti-IL-7R\u03b1 antibody, and ADX-097, a tissue-targeted protein therapeutic. Q32 Bio completed a $60 million Series B financing round under his leadership.
Full founder directory · Investor directory · Company funding database · Fundraising library